Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy
AJ Lenneman, L Wang, M Wigger, H Frangoul… - The American journal of …, 2013 - Elsevier
In 2015, there will be an estimated 11.3 million cancer survivors. With an increasing
population of cancer survivors, it is imperative to understand the treatment options available …
population of cancer survivors, it is imperative to understand the treatment options available …
Heart Transplant Survival Outcomes for Adriamycin-Dilated Cardiomyopathy
AJ Lenneman, L Wang, M Wigger, H Frangoul… - The American Journal of …, 2013 - infona.pl
In 2015, there will be an estimated 11.3 million cancer survivors. With an increasing
population of cancer survivors, it is imperative to understand the treatment options available …
population of cancer survivors, it is imperative to understand the treatment options available …
Heart Transplant Survival Outcomes for Adriamycin-Dilated Cardiomyopathy
AJ Lenneman, L Wang, M Wigger… - American Journal of …, 2013 - ajconline.org
In 2015, there will be an estimated 11.3 million cancer survivors. With an increasing
population of cancer survivors, it is imperative to understand the treatment options available …
population of cancer survivors, it is imperative to understand the treatment options available …
Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy.
AJ Lenneman, L Wang, M Wigger… - The American Journal …, 2012 - europepmc.org
In 2015 there will be an estimated 11.3 million cancer survivors. With a growing population
of cancer survivors, it is imperative to understand treatment options and outcomes for …
of cancer survivors, it is imperative to understand treatment options and outcomes for …
[引用][C] Heart Transplant Survival Outcomes for Adriamycin-Dilated Cardiomyopathy
AJ Lenneman, L Wang, M Wigger, H Frangoul… - The American Journal …, 2013 - cir.nii.ac.jp
Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy
AJ Lenneman, L Wang, M Wigger… - The American …, 2013 - pubmed.ncbi.nlm.nih.gov
In 2015, there will be an estimated 11.3 million cancer survivors. With an increasing
population of cancer survivors, it is imperative to understand the treatment options available …
population of cancer survivors, it is imperative to understand the treatment options available …
Heart Transplant Survival Outcomes for Adriamycin-Dilated Cardiomyopathy
AJ Lenneman, L Wang, M Wigger… - … American Journal of …, 2013 - search.proquest.com
In 2015, there will be an estimated 11.3 million cancer survivors. With an increasing
population of cancer survivors, it is imperative to understand the treatment options available …
population of cancer survivors, it is imperative to understand the treatment options available …
[HTML][HTML] Heart Transplant Survival Outcomes for Adriamycin Dilated Cardiomyopathy
AJ Lenneman, L Wang, M Wigger… - The American journal …, 2013 - ncbi.nlm.nih.gov
In 2015 there will be an estimated 11.3 million cancer survivors. With a growing population
of cancer survivors, it is imperative to understand treatment options and outcomes for …
of cancer survivors, it is imperative to understand treatment options and outcomes for …
Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy.
AJ Lenneman, L Wang, M Wigger… - The American Journal …, 2012 - europepmc.org
In 2015 there will be an estimated 11.3 million cancer survivors. With a growing population
of cancer survivors, it is imperative to understand treatment options and outcomes for …
of cancer survivors, it is imperative to understand treatment options and outcomes for …
[引用][C] Heart Transplant Survival Outcomes in Adriamycin Dilated Cardiomyopathy
AJ Lenneman, H Frangoul, DB Sawyer… - Journal of Cardiac …, 2012 - infona.pl
Heart Transplant Survival Outcomes in Adriamycin Dilated Cardiomyopathy × Close The
Infona portal uses cookies, ie strings of text saved by a browser on the user's device. The …
Infona portal uses cookies, ie strings of text saved by a browser on the user's device. The …